192
Participants
Start Date
June 30, 2008
Primary Completion Date
December 31, 2011
Study Completion Date
August 31, 2012
CAL-101
CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
Weill Medical College of Cornell, New York
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore
Sarah Cannon Research Institute, Nashville
The Ohio State University Medical Center, Columbus
Washington University School of Medicine, St Louis
Stanford Cancer Center, Palo Alto
Dana-Farber Cancer Institute, Boston
Oregon Health and Science University, Portland
University of Wisconsin, Madison
Lead Sponsor
Gilead Sciences
INDUSTRY